Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
REVA Medical, Inc. (RVA.AX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/05/2020 8-K Quarterly results
01/15/2020 8-K Filed for Chapter 11
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbol Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Se...",
"Restructuring Support Agreement, by and between the debtors and the Supporting Lenders",
"REVA Medical Files for Court Approval of Prepackaged Plan of Reorganization"
12/13/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Announcement entitled, “Corporate Update”",
"Announcement entitled, “Corporate Update”"
08/07/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "First Amendment to Credit and Guaranty Agreement",
"Announcement entitled, “REVA Receives Additional Interim Funding”"
04/08/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amendment #5 to the Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company",
"Credit and Guaranty Agreement by and between Goldman Sachs International, Various Lenders and the Company",
"dated as of April 2, 2019 by and among EACH OF THE GRANTORS PARTY HERETO and GOLDMAN SACHS INTERNATIONAL, as Collateral Agent",
"Announcement entitled, “REVA Receives Interim Funding and Enters into an Amendment to License Agreement with Rutgers, The State University of New Jersey”"
02/25/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/19/2019 8-K Quarterly results
02/04/2019 8-K Quarterly results
01/17/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Executive Employment Agreement, effective as of January 4, 2019, by and between the Company and Leigh Elkolli"
01/03/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "REVA MEDICAL REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS"
09/24/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “Primary PCI in STEMI with sirolimus eluting FANTOM bioresorbable vascular scaffold first guided with optical coherence tomography – acute results from a FANTOM STEMI pilot study”",
"Presentation entitled “FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-Up Clinical Outcomes Final Results”",
"Presentation entitled “Two-year healing patterns after implantation of the FANTOM bioresorbable scaffold”",
"Presentation entitled “On-going Activities with a Radiopaque Tyrosine-Carbonate-Based Polymeric BRS: Fantom”"
08/03/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company",
"Amendment #4 to Exclusive License Agreement Number 2, by and between Rutgers, The State University of New Jersey and the Company"
06/26/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “REVA Medical Corporate Presentation June 2018”"
05/23/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FANTOM’S POSITIVE TWO-YEAR RESULTS SHOW SUSTAINED SAFETY AND EFFICACY"
05/23/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “New 24-month data from the FANTOM II clinical trial and initial results from Fantom BRS expansion trials”",
"Presentation entitled “Tyrocore: a proprietary polymer uniquely designed for vascular scaffolds”",
"Presentation entitled “Insights from the FANTOM II serial OCT sub-study”",
"Presentation entitled “Fantom BRS case reviews and introduction to the REVA Technique”"
03/26/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “REVA Medical Corporate Presentation March 2018”"
03/07/2018 8-K Quarterly results
Docs: "REVA MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS"
02/05/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "REVA ANNOUNCES APPOINTMENT OF STEPHEN OESTERLE, MD TO BOARD OF DIRECTORS"
01/08/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “REVA Medical Corporate Presentation January 2018”"
11/08/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “REVA Medical Corporate Presentation November 2017”"
11/07/2017 8-K Quarterly results
Docs: "REVA MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS"
10/31/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation entitled “Fantom: A Radiopaque “Stent-Like” BRS with Improved Expansion Characteristics”"
10/31/2017 8-K Quarterly results
10/11/2017 8-K Quarterly results
08/04/2017 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Announcement entitled, “Boston Scientific’s Distribution Option Lapses”"
07/31/2017 8-K Form 8-K - Current report:
07/19/2017 8-K Form 8-K - Current report:
06/20/2017 8-K Form 8-K - Current report
06/05/2017 8-K Form 8-K - Current report
05/18/2017 8-K Form 8-K - Current report
05/16/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy